Medication info

Empagliflozin and Linagliptin Tablets 10/5 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›5mg / 1 tabletEmpagliflozin Amorphous›10mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Yellow film-coated tablets that are round and convex on both sides
Packaging
Bottle) 30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202502451 · Approved 2025.09.16

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended starting dose of this medicine is empagliflozin 10 mg/linagliptin 5 mg once daily. If empagliflozin 10 mg/linagliptin 5 mg is tolerated and additional glycemic control is needed, the dose may be increased to 25/5 mg once daily. Patients switching to this medicine from concomitant therapy with empagliflozin and linagliptin should receive the doses they were previously taking. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. However, if it is within 12 hours of the next dose, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Special populations Patients with renal impairment This medicine is not recommended for patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2 for the purpose of improving glycemic control. No dose adjustment is required in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in these patients. Older adults No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with diet and exercise to assist in blood sugar control for patients with type 2 diabetes. The components empagliflozin and linagliptin act together to effectively improve blood sugar levels. Therefore, this medication is used for blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The recommended starting dose of this medicine is empagliflozin 10 mg/linagliptin 5 mg once daily. If empagliflozin 10 mg/linagliptin 5 mg is tolerated and additional glycemic control is needed, the dose may be increased to 25/5 mg once daily. Patients switching to this medicine from concomitant therapy with empagliflozin and linagliptin should receive the doses they were previously taking. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. However, if it is within 12 hours of the next dose, skip the missed dose and take the next dose at the usual scheduled time. Do not take a double dose in one day. Special populations Patients with renal impairment This medicine is not recommended for patients with an estimated glomerular filtration rate (eGFR) below 45 ml/min/1.73m2 for the purpose of improving glycemic control. No dose adjustment is required in patients with an estimated glomerular filtration rate of 45 ml/min/1.73m2 or higher. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in these patients. Older adults No dose adjustment is required based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older.

Precautions

This medication contains two components, empagliflozin and linagliptin, and is primarily used for the treatment of type 2 diabetes. First, this medication should not be used by individuals allergic to empagliflozin or linagliptin, or any other components of this medication, by patients with type 1 diabetes, diabetic ketoacidosis, or patients undergoing kidney dialysis. Since this medication may affect kidney function, it is important to have regular kidney function tests before and during treatment. Care should be taken in patients with decreased kidney function. For patients with mild to moderate heart failure, caution is advised; it is not recommended for patients with severe heart failure. The linagliptin component may rarely cause acute pancreatitis; if severe abdominal pain persists, discontinue use immediately and consult your doctor. Additionally, linagliptin may rarely trigger bullous pemphigoid; if any skin abnormalities occur, inform healthcare personnel immediately. The most commonly reported side effect while taking this medication is urinary tract infection, which may occur more frequently in females. Genital infections may also occur, so inform a healthcare professional if symptoms arise. Hypoglycemia has also been reported, especially when used in conjunction with insulin or sulfonylurea medications, so caution is advised regarding hypoglycemia risks. Patients with low blood pressure or inadequate fluid volume, as well as elderly patients over 75 years of age, are at risk of dehydration or hypotension, and their condition should be closely monitored while using this medication. This medication may rarely cause a serious metabolic disorder called ketoacidosis in patients with diabetes, so immediate treatment is necessary if symptoms like vomiting, abdominal pain, or difficulty breathing occur. Furthermore, this medication may affect lithium concentrations in the blood; if undergoing lithium treatment, frequent monitoring of blood levels is necessary. It is generally recommended not to use this medication during pregnancy unless absolutely necessary, and it is advised to discontinue breastfeeding if nursing. Safety and efficacy have not been confirmed in children under 18, and it is best not to use this medication in this age group. Finally, while taking this medication, caution is advised when driving or operating machinery due to the risk of accidents from hypoglycemia. If any unusual symptoms develop during treatment, consult healthcare personnel immediately.

Side effects

  • Urinary Tract Infection
  • Vulvar Vulvitis
  • Balanitis
  • Pharyngitis
  • Fournier's Gangrene
  • Hypersensitivity
  • Angioedema
  • Urticaria
  • Hypoglycemia
  • Thirst
Show 159 more
  • Ketoacidosis
  • Cough
  • Constipation
  • Pancreatitis
  • Oral Ulcer Formation
  • Itching
  • Rash
  • Vesicular Pemphigoid
  • Rhabdomyolysis
  • Blood Volume Depletion
  • Increased Urination
  • Urinary Difficulty
  • Interstitial Nephritis
  • Increased Amylase
  • Increased Lipase
  • Increased Hematocrit
  • Increased Serum Lipids
  • Increased Blood Creatinine
  • Decreased Glomerular Filtration Rate
  • Epigastric Pain
  • Small Intestine-Colon Inflammation
  • Intestinal Obstruction
  • Gastroenteritis
  • Herpes Zoster
  • Cystitis
  • Acute Pyelonephritis
  • Bronchitis
  • Vestibular Neuronitis
  • Sepsis
  • Pneumonia
  • Decreased Appetite
  • Dehydration
  • Hyperglycemia
  • Cerebral Infarction
  • Speech Disorder
  • Alzheimer's Disease
  • Chest Pain
  • Fever
  • Facial Edema
  • Fatigue
  • Death
  • Chronic Obstructive Pulmonary Disease
  • Asthma
  • Diabetic Foot
  • Skin Lesions
  • Acute Kidney Injury
  • End-Stage Renal Disease
  • Acute Cholangitis
  • Acute Cholecystitis
  • Cholangitis
  • Dizziness
  • Renal Transplant Failure
  • Diarrhea
  • Vomiting
  • Irritable Bowel Syndrome
  • Colitis
  • Abdominal Discomfort
  • Dysphagia
  • Gastric Ulcer
  • Gum Bleeding
  • Tooth Loss
  • Hemorrhoids
  • Lower Abdominal Pain
  • Hypopigmentation
  • Rhinitis
  • Soft Tissue Infection
  • Pharyngitis
  • Tsutsugamushi Disease
  • Periodontitis
  • Tonsillitis
  • Laryngitis
  • Viral Upper Respiratory Infection
  • Decreased Appetite
  • Hypercholesterolemia
  • Inadequate Control of Diabetes
  • Malnutrition
  • Hyponatremia
  • Headache
  • Drowsiness
  • Chest Discomfort
  • Asthenia
  • Epistaxis
  • Oropharyngeal Pain
  • Voice Disorder
  • Allergic Rhinitis
  • Productive Cough
  • Rhinorrhea
  • Androgenetic Alopecia
  • Hyperhidrosis
  • Hair Loss
  • Anxiety
  • Insomnia
  • Depression
  • Contusion
  • Bone Contusion
  • Concussion
  • Meniscus Injury
  • Fractured Toe
  • Hand Fracture
  • Pneumoconiosis
  • Palpitations
  • Tachycardia
  • Arteriosclerosis
  • Deep Venous Thrombosis
  • Diabetic Vascular Disease
  • Peripheral Arterial Occlusive Disease
  • Goiter
  • Anemia
  • Lymphadenopathy
  • Vulvar Pruritus
  • Genital Pruritus
  • Hypoglycemia
  • Obesity
  • Hypersalivation
  • Vitamin D Deficiency
  • Dermal Cyst
  • Seborrheic Dermatitis
  • Atopic Dermatitis
  • Nummular Eczema
  • Heat Rash
  • Sebaceous Gland Hyperplasia
  • Lumbar Spinal Canal Stenosis
  • Myalgia
  • Limb Pain
  • Musculoskeletal Chest Pain
  • Cervical Stenosis
  • Fibromyalgia
  • Flank Pain
  • Fracture Pain
  • Muscle Weakness
  • Osteoarthritis
  • Osteoporosis
  • Rotator Cuff Syndrome
  • Astigmatism
  • Allergic Conjunctivitis
  • Blurred Vision
  • Corneal Erosion
  • Macular Fibrosis
  • Eye Discomfort
  • Ocular Hyperemia
  • Pathological Myopia
  • Retinal Detachment
  • Retinal Crystal
  • Retinal Vein Occlusion
  • Perforating Retinal Detachment
  • Eyelid Swelling
  • Visual Impairment
  • Vitreous Floaters
  • Vitreous Hemorrhage
  • Nasal Hemorrhage
  • Exercise-Induced Dyspnea
  • Residual Phlegm
  • Nasal Hemorrhage
  • Otalgia
  • Positional Vertigo
  • Vertigo
  • Erectile Dysfunction
  • Hypothyroidism
  • Thyroid Nodule

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius to preserve the medication's effectiveness and safety.

Appearance and packaging

Appearance

Yellow film-coated tablets that are round and convex on both sides

Package unit

Bottle) 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.